

REJUVENOL[®]

MATERIAL SAFETY DATA SHEET

1. PRODUCT AND COMPANY IDENTIFICATION

ARGANIA SERUM LITE

Principal Use: Styling, Shine

Physical Form: Liquid.

Color: Colorless

Odor: Fragranced .

NFPA Profile: Health: 1, Flammability : 2 Instability/Reactivity : 0

Rejuvenol Laboratories

130 Lincoln St.

Copiague, NY 11726

Only in the event of a transportation emergency involving spills, leaks, fires or accidents, call CHEMTREC at 1-800-424-9300

2. COMPOSITION/INFORMATION ON INGREDIENTS

INCI NAME *	CAS NUMBER	% w/w **
Cyclopentasiloxane	541-02-6	A
Cyclotetrasiloxane	69430-24-6	E
Dimethiconol	31692-79-2	E
Argania Spinosa Kernel Oil	299184-75-1	E
Fragrance (Parfum)	N/A	F
Linum Usitatissimum (Linseed) Seed Oil	8001-26-1	F
Tocophery Acetate	58-95-7	F
Daucus Carota Sativa (Carrot) Seed Oil	8015-88-1	E
Benzyl Salicylate	118-58-1	F
Limonene	5989-27-5	F
Hydroxycitronellol	107-75-5	F
Butylphenyl Methylpropional	80-54-6	F
Linalool	78-70-6	F
Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde	31906-04-4	F

(*) CTFA DICTIONARY

(**) FDA-CODE (A= >50%, B= 25-50%, C= 10-25%, D= 5-10%, E= 1-5%, F=0.1-1%, G=<0.1%)

VOC Content: 0%

REJUVENOL[®]

3.- Hazards Identification

Acute Effects

	<u>Potential Effects</u>
Eye:	Direct contact may cause irritation
Skin:	No Significant Irritation expected from a single short-term exposure.
Inhalation:	No Significant Effects expected from a single short-term exposure.
Oral:	No Significant Effects expected from a single short-term exposure.

Prolonged/Repeated Exposure Effects

Skin:	Not known at this time.
Inhalation:	Overexposure by inhalation may injure reproductive system.
Oral:	No known at this time.

Signs and Symptoms of Overexposure

None known

Medical Conditions Aggravated by Exposure

None Known

Carcinogenic Status

None Known

4.- First Aid Measures

First Aid Eyes:

Immediately flush eyes with plenty of water. After initial flushing, remove any contact lenses and continue flushing for at least 15 min. Have eyes examined and treated by medical personnel.

First Aid – Skin

No first aid should be needed.

First Aid – Ingestion

No first Aid should be needed.

First Aid – Inhalation

If affected, remove to fresh air.

5.- Fire Fighting Measures

Flash Point and Method

170.6 ° F / 77 ° C (Tag Closed Cup)

171 °F / 77.2 °C (Cleveland Open Cup)

Auto ignition Temperature

737.6° F / 392 ° C

Explosive Limits

Lower limit: 0.70 %

REJUVENOL[®]

General Hazards

Static electricity will accumulate and might ignite vapors. Prevent a possible fire hazard by bonding and grounding or inert gas purge.

Extinguishing Media

On large fires use dry chemical, foam or water spray. On small fires use carbon dioxide (CO₂), dry chemical or water spray. Water can be used to cool fire exposed containers.

Fire Fighting Equipment

Self Contained breathing apparatus with full face piece and protective clothing.

6.-Containment and Cleanup

Remove possible Ignition sources. Determine whether to evacuate or isolate the area according to your local emergency plan. Clean area as appropriate since spilled material, even in small quantities, may present a slip hazard. Clean up materials from spill with suitable absorbent. Local, state and federal laws and regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases.

7.-HANDLING and STORAGE

Use with adequate ventilation. Avoid eye contact.

Static electricity will accumulate and may ignite vapors. Prevent a possible fire hazard by bonding and grounding or inert gas purge. Keep container closed and away from heat, sparks and flame.

8.-EXPOSURE CONTROLS/PERSONNEL PROTECTION

CAS Number

541-02-6

Component Name

Cyclopentasiloxane

Exposure Limits

TWA 10 ppm.

Component Exposure Limits: As per component composition.

All components are below allowable exposure limits under normal daily use by any adult.

Engineering Controls

Local ventilation: Recommended

General Ventilation: Recommended

9.-PHYSICAL AND CHEMICAL PROPERTIES

Physical Form: Liquid
Color: Colorless
Odor: Fragranced
Specific Gravity @ 25°C: 0.95
Viscosity: 3.8 mm²/s
Freezing/Melting Point:-44 °C
Boiling Point: 211 °C
Vapor Pressure: Not Determined
Solubility in Water: <0.05 mg/l

10.- STABILITY AND REACTIVITY.

STABILITY
Stable under normal temperature conditions and recommended use.
REACTIVITY

REJUVENOL[®]

	Not Known.
11.- TOXICOLOGICAL INFORMATION	
<u>Acute Toxicological Data for Cyclopentasiloxane</u>	
Species	Test Results
Inhalation LC50: Rat	8.67 mg/l
	Type Of Test
	4hr dust/mist
<u>Component Toxicology Information on Cyclopentasiloxane</u>	
<p>Results from a 2 year repeated vapour inhalation exposure study to rats of Cyclopentasiloxane (D5) indicate effects (uterine endometrial tumors) in female animals. This finding occurred at the highest exposure dose (160 ppm) only. Studies to date have not demonstrated if this effect occurs through a pathway that is relevant to humans. Based on the available information on its potential to cause harm to human health, Health Canada, in a 2008 screening assessment , has concluded that D5 is not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.</p> <p><u>Special Hazard Information on Components</u> No known applicable information.</p>	
12.- ECOLOGICAL INFORMATION	ECOTOXICITY The product is not expected to be hazardous to the environment.
13.- DISPOSAL CONSIDERATIONS	Dispose of waste and residues in accordance with local authority requirements. No classified ad a hazardous waste
14.-TRANSPORT INFORMATION	This product is not covered by International Regulation on the transport of dangerous goods (IMDG, IATA, ADR/RID).
15.-REGULATORY INFORMATION	National Regulations Cosmetic Products (Safety) Regulations
16.-OTHER INFORMATION	REVISION DATE: 06-2011 These data are offered in good faith as typical values and not as product specifications. No warranty, either expressed or implied, is hereby made. The recommended industrial hygiene and safe handling procedures are believe to be generally applicable. However, each user should review these recommendations in the specific context of the intended use and determine whether they are appropriate.